AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

This study has been completed.

Sponsor:

Collaborator:

Amgen

Information provided by (Responsible Party):

Ahmad Tarhini, University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT01233687

First received: November 2, 2010

Last updated: June 20, 2017

Last verified: May 2017

History of Changes

Results First Received: January 12, 2016

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment; Masking: No masking; Primary Purpose: Treatment
Condition:	Carcinoma, Non-Small-Cell Lung
Intervention:	Drug: AMG 102 and erlotinib

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
AMG 102 + Erlotinib	No text entered.

Participant Flow for 2 periods

Period 1: Phase I RP2D AMG 102 + Erlotinib

	AMG 102 + Erlotinib
STARTED	7
COMPLETED	7
NOT COMPLETED	0

Period 2: Phase II AMG 102 + Erlotinib

	AMG 102 + Erlotinib
STARTED	49 ^[1]
Response-Evaluable	45
COMPLETED	45
NOT COMPLETED	4
Death	1
Physician Decision	2
Withdrawal by Subject	1

^[1]	Includes 7 participants from Phase 1 part of study.

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
AMG 102 + Erlotinib	No text entered.

Baseline Measures

	AMG 102 + Erlotinib
Overall Participants Analyzed [Units: Participants]	45

Age [Units: Years] Median (Full Range)	65 (35 to 82)

Sex: Female, Male [Units: Participants] Count of Participants
Female	20 44.4%
Male	25 55.6%

Outcome Measures

Show All Outcome Measures

1. Primary:

Percentage of Participants That Experienced a Dose Limiting Toxicity [ Time Frame: During first cycle of treatment (3 weeks) ]

Show Outcome Measure 1

2. Primary:

Disease Control Rate (DCR) [ Time Frame: Six weeks from initiation of treatment with AMG 102 + Erlotinib ]

Show Outcome Measure 2

3. Secondary:

Objective Response Rate (ORR/Clinical Response) [ Time Frame: Up to 6 months ]

Show Outcome Measure 3

4. Secondary:

Progression-free Survival (PFS) [ Time Frame: Up to 24 months (after the first patient is accrued) ]

Show Outcome Measure 4

5. Secondary:

Overall Survival (OS) [ Time Frame: Up to 24 months (after the first evaluable patient is accrued) ]

Show Outcome Measure 5

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:

Name/Title: Ahmad Tarhini, MD
Organization: University of Pittsburgh
phone: (412) 648-6578
e-mail: tarhiniaa@upmc.edu

Responsible Party:	Ahmad Tarhini, University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT01233687 History of Changes
Other Study ID Numbers:	10-058
Study First Received:	November 2, 2010
Results First Received:	January 12, 2016
Last Updated:	June 20, 2017

To Top